Sort   by:  
 Page size 
MetabolomicsTemporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
Lung cancer causes more deaths in men and women than any other cancer related disease. Currently, few effective strategies exist to predict how patients will respond to treatment. We evaluated the serum metabolomic profiles of 25 lung cancer patients undergoing chemotherapy ± radiation to evaluate t...
2017-01-19 | MTBLS200 | MetaboLights
MetabolomicsSerum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population

PURPOSE: Detecting signals of micrometastatic disease in early breast cancer (EBC) patients could improve risk stratification and allow better tailoring of adjuvant therapies. We have previously shown that postoperative serum metabolomic profiles are predictive of relapse in a si...

2017-03-02 | MTBLS424 | MetaboLights
MetabolomicsMonounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
Changes in cellular lipid metabolism are a common feature in most solid tumors, which occur already in early stages of the tumor progression. However, it remains unclear if the tumor-specific lipid changes can be detected at the level of systemic lipid metabolism. The objective of this study was to ...
2014-06-17 | MTBLS92 | MetaboLights
MetabolomicsCombined metabolomics with transcriptomics reveals important serum biomarkers correlated with lung cancer proliferation through calcium signaling pathway

Lung cancer (LC) is still one of the most deadly cancers in the world, but there is a lack of non-invasive biomarkers to assist diagnosis and guide treatment. Herein, untargeted serum metabolomics of 57 LC patients and 59 HC people was performed based on gas chromatography-mass spectrography (GC-...

2025-04-29 | MTBLS1517 | MetaboLights
MetabolomicsDynamic Changes and Clinical Significance of Gut Microbiota and Serum Metabolites in Breast Cancer Onset, Progression and Chemotherapy Intervention

Background: Breast cancer progression and treatment are increasingly linked to systemic metabolic and microbial alterations. Previous studies have identified distinct gut microbiome profiles and serum metabolite shifts in breast cancer patients compared to healthy individuals, yet longitudi...

2026-05-08 | MTBLS13634 | MetaboLights
MetabolomicsUntargeted Serum Metabolomics Reveals Differential Signatures in Gallstone-Associated and Gallstone-Free Gallbladder Cancer

Gallbladder cancer (GBC) is an aggressive malignancy often associated with gallstones (GBCGS), a condition distinct from gallstone disease (GSD). Both GBC and GBCGS are rare, with unclear pathogenesis and no established biomarker-based solutions. This pilot study aimed to identify distinct metabo...

2025-12-22 | MTBLS12514 | MetaboLights
MetabolomicsUse of UHPLC-HRMS to profile the metabolites from the serum of breast cancer patients

Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related mortality in women worldwide. As such exploring the metabolic changes during human breast carcinogenesis is important for developing disease prevention methods and treatments. In the present study, non-target...

2024-02-13 | MTBLS8920 | MetaboLights
MetabolomicsSerum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer (Untargeted assay)

BACKGROUND: Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are current clinical challenges.

METHODS: The serum metabolites of 20 healthy individuals and patients with prosta...

2023-04-17 | MTBLS6039 | MetaboLights
MetabolomicsSerum lipidomics study looking for specific endometrial polyps biomarkers distinguishing from endometrial cancer or hyperplasia

Endometrial diseases are common gynecological diseases that disorder women of childbearing age and perimenopausal women, including endometrial polyps (EP), endometrial cancer (EC), and endometrial hyperplasia (EH). Clinically, biopsy or imaging methods are usually used to screen and diagnose...

2022-01-14 | MTBLS3444 | MetaboLights
MetabolomicsSerum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer (Targeted organic acid assay)

BACKGROUND: Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are current clinical challenges.

METHODS: The serum metabolites of 20 healthy individuals and patients with prostat...

2023-04-17 | MTBLS6038 | MetaboLights
Sort   by:  
 Page size